Analysis, trends and data stories from the Clival team, newest first.
Featured
The global herbal medicine market is booming, and at its heart lies Traditional Chinese Medicine (TCM).
Read article
Antimicrobial resistance (AMR) is getting scary. Experts say that by 2050, it could cause 10 million deaths every year if we don’t act.
Read article
Generics and biosimilars both make drugs cheaper, but they behave very differently after a patent dies.
Read article
For pharma leaders, investors, and business development teams, these five years represent both risk and opportunity on a historic scale.
Read article
Here’s what that means: traditional anticoagulants—like warfarin and LMWHs—still form the backbone of hospital and community care
Read article
Companies have realized the era of innovation and advance drug developments is around the corner. One of the key areas that is witnessing a surge is monoclonal antibodies.
Read article
Artificial intelligence (AI) has become a transformative force in the increasingly digitized healthcare environment.
Read article
2025 is not just another year, a wave of innovation is crashing through biotech and bioinformatics, reshaping every stage of clinical development.
Read article
AI is no longer a distant vision in healthcare. It’s a $13.8 billion market today—and it's projected to soar past $164 billion by 2029. That’s over 1,000% growth in just a few years.
Read article
Clinical trials are drowning in data. That's not hyperbole—it's mathematics.
Read articlePage 4 of 9 · 84 articles